 |
|
A Prospective Trial of Structured Treatment Interruptions in Human Immunodeficiency Virus Infection
Catherine Fagard, MD;
Annette Oxenius, PhD;
Huldrych Günthard, MD;
Felipe Garcia, MD;
Michelle Le Braz, RN;
Gabriel Mestre, MD;
Manuel Battegay, MD;
Hansjakob Furrer, MD;
Pietro Vernazza, MD;
Enos Bernasconi, MD;
Amalio Telenti, MD;
Rainer Weber, MD;
Dominique Leduc, MD;
Sabine Yerly, PhD;
David Price, MD;
Sara J. Dawson, PhD;
Thomas Klimkait, MD;
Thomas V. Perneger, MD;
Angela McLean, PhD;
Bonaventura Clotet, MD;
José M. Gatell, MD;
Luc Perrin, MD;
Montserrat Plana, MD;
Rodney Phillips, MD;
Bernard Hirschel, MD; for the Swiss HIV Cohort Study
Arch Intern Med. 2003;163:1220-1226.
Background According to the "autovaccination hypothesis," reexposure to human immunodeficiency virus (HIV) during treatment interruptions may stimulate the HIV-specific immune response and lead to low viremia after withdrawal of highly active antiretroviral treatment (HAART). Many patients who started HAART earlier in their disease course than is currently recommended would like to discontinue, but it is unknown whether it is safe to do so.
Objectives To determine whether repeated treatment interruptions of HAART (1) stimulated the cytotoxic HIV-specific immune response and whether such stimulation correlated with low viremia off treatment, and (2) were safe with respect to clinical complications, development of viral resistance, and decline in CD4 cell counts.
Design Interventional study with before-after comparison.
Setting Outpatient clinics of university hospitals in Switzerland and Spain.
Patients A total of 133 patients receiving HAART, with a median CD4 cell count of 740/µL, and whose viral load had been undetectable for a median of 21 months.
Interventions HAART was interrupted for 2 weeks, restarted, and continued for 8 weeks. After 4 such cycles, treatment was indefinitely suspended 40 weeks after study entry.
Main Outcome Measures HIV-specific cytotoxic T-cell responses were evaluated by interferon  enzyme-linked immunospot analysis. The proportion of "responders" (viral load <5000 copies/mL) was measured at weeks 52 and 96. HIV-related diseases and CD4 cell counts were recorded.
Results Seventeen percent of patients (95% confidence interval, 11%-25%) were responders at week 52, and 8% at week 96. Low pre-HAART viral load and lack of rebound during weeks 0 to 40 predicted response. HIV-specific CD8+ T cells increased between week 0 (median, 343 spot-forming cells per million peripheral blood lymphocytes [SFC/106 PBL]) and week 52 (median, 1930 SFC/106 PBL), but there was an inverse correlation between response and the number of spot-forming cells. Eighty-five (64%) of 133 patients stopped therapy for at least 12 weeks, and 55 (41%) for at least 56 weeks. The median CD4 cell count decreased from 792/µL to 615/µL during the first 12 weeks without treatment, but stabilized thereafter. One patient (0.75%) developed drug resistance necessitating salvage treatment. There were no AIDS-related clinical complications.
Conclusions Results of this study do not favor the autovaccination hypothesis. Treatment interruptions did not provoke clinical complications, and there was little drug resistance. Comparative trials will have to show what benefit, if any, is associated with intermittent, as opposed to continuous treatment.
From the Division of Infectious Diseases (Drs Fagard and Hirschel and Ms Le Braz), the Laboratory of Virology (Drs Yerly and Perrin), and the Quality of Care Unit (Dr Perneger), Geneva University Hospital, Geneva, Switzerland; Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, England (Drs Oxenius, Price, Dawson, and Phillips); Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital, Zurich, Switzerland (Drs Günthard and Weber); Infectious Disease Service, Clinical Institute of Infections and Immunology, Hospital Clinic, Barcelona, Spain (Drs Garcia, Mestre, Gatell, and Plana); Center for HIV Research, Outpatient Department of Internal Medicine, University Hospital, Basel, Switzerland (Drs Battegay and Klimkait); Division of Infectious Diseases, Inselspital, Berne, Switzerland (Dr Furrer); Medizinische Klinik, University Hospital, St Gallen, Switzerland (Dr Vernazza); Ospedale Civico, Lugano, Switzerland (Dr Bernasconi); Division of Infectious Diseases, CHUV, Lausanne, Switzerland (Dr Telenti); Centre Hospitalier, Hôpital d'Ambilly, d'Ambilly, France (Dr Leduc); Wellcome Trust Center for Epidemiology of Infectious Disease and Zoology Department, Oxford, England (Dr McLean); and Germans Trias i Pujol, Hospital Universitari i Fundacio irsiCaixa, Badalona/Barcelona, Spain (Dr Clotet). The authors have no relevant financial interest in this article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Therapeutic Vaccination with Simian Immunodeficiency Virus (SIV)-DNA+IL-12 or IL-15 Induces Distinct CD8 Memory Subsets in SIV-Infected Macaques
Halwani et al.
J. Immunol. 2008;180:7969-7979.
ABSTRACT
| FULL TEXT
Virological Outcome after Structured Interruption of Antiretroviral Therapy for Human Immunodeficiency Virus Infection Is Associated with the Functional Profile of Virus-Specific CD8+ T Cells
Daucher et al.
J. Virol. 2008;82:4102-4114.
ABSTRACT
| FULL TEXT
Emergence of Polyfunctional CD8+ T Cells after Prolonged Suppression of Human Immunodeficiency Virus Replication by Antiretroviral Therapy
Rehr et al.
J. Virol. 2008;82:3391-3404.
ABSTRACT
| FULL TEXT
Immunological Responses and Long-Term Treatment Interruption after Human Immunodeficiency Virus Type 1 (HIV-1) Lipopeptide Immunization of HIV-1-Infected Patients: the LIPTHERA Study
Pialoux et al.
CVI 2008;15:562-568.
ABSTRACT
| FULL TEXT
Effective T-Cell Responses Select Human Immunodeficiency Virus Mutants and Slow Disease Progression
Frater et al.
J. Virol. 2007;81:6742-6751.
ABSTRACT
| FULL TEXT
Trials That Matter: CD4+ T-Lymphocyte Count-Guided Interruption of Antiretroviral Therapy in HIV-Infected Patients
Jacobson et al.
ANN INTERN MED 2007;146:682-683.
FULL TEXT
Passive Sexual Transmission of Human Immunodeficiency Virus Type 1 Variants and Adaptation in New Hosts
Frater et al.
J. Virol. 2006;80:7226-7234.
ABSTRACT
| FULL TEXT
Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.
Van Rompay et al.
J. Virol. 2006;80:6399-6410.
ABSTRACT
| FULL TEXT
Antiretroviral treatment of HIV infected adults.
Deeks
BMJ 2006;332:1489-1489.
FULL TEXT
State of HIV Treatment: Results of the International Association of Physicians in AIDS Care Surveys of HIV-Positive Patients and HIV-Treating Physicians in the United States
Zuniga
J Int Assoc Physicians AIDS Care (Chic Ill) 2006;5:51-56.
ABSTRACT
Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infection
Boschi et al.
J Antimicrob Chemother 2006;57:520-526.
ABSTRACT
| FULL TEXT
The Cost-Effectiveness of Expanded Testing for Primary HIV Infection
Coco
Ann Fam Med 2005;3:391-399.
ABSTRACT
| FULL TEXT
Low Human Immunodeficiency Virus Envelope Diversity Correlates with Low In Vitro Replication Capacity and Predicts Spontaneous Control of Plasma Viremia after Treatment Interruptions
Joos et al.
J. Virol. 2005;79:9026-9037.
ABSTRACT
| FULL TEXT
Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors
Rusert et al.
J. Virol. 2005;79:8454-8469.
ABSTRACT
| FULL TEXT
Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point
Trkola et al.
Blood 2004;104:1784-1792.
ABSTRACT
| FULL TEXT
Where Does HIV Live?
Stebbing et al.
NEJM 2004;350:1872-1880.
FULL TEXT
Role of therapeutic vaccines in the control of HIV-1
Kinloch-de Loes
J Antimicrob Chemother 2004;53:562-566.
ABSTRACT
| FULL TEXT
Costs associated with combination antiretroviral therapy in HIV-infected patients
Yazdanpanah
J Antimicrob Chemother 2004;53:558-561.
ABSTRACT
| FULL TEXT
Immunosuppressive drugs as an adjuvant to HIV treatment
Fumero et al.
J Antimicrob Chemother 2004;53:415-417.
ABSTRACT
| FULL TEXT
Human Immunodeficiency Virus Type 1 Fitness Is a Determining Factor in Viral Rebound and Set Point in Chronic Infection
Trkola et al.
J. Virol. 2003;77:13146-13155.
ABSTRACT
| FULL TEXT
Disappointing Data on STI
AIDS Clin Care 2003;2003:2-2.
FULL TEXT
|
